Mitochondrial Dysfunction in Type 2 Diabetes and Metabolic Syndrome: Mechanisms, Biomarkers, and Emerging Therapies.

<h4>Background</h4>Mitochondrial dysfunction(definition) is increasingly recognized as a bidirectional component of type 2 diabetes (T2D) and metabolic syndrome, linking nutrient excess, lipotoxicity, oxidative stress, inflammation, impaired insulin signaling, and pancreatic β-cell failure. However, its causal position and clinical actionability remain uncertain because mitochondrial abnormalities vary by tissue, disease stage, and metabolic phenotype.<h4>Objective</h4>To critically synthesize mechanistic, biomarker, imaging, and therapeutic evidence concerning mitochondrial dysfunction in T2D and metabolic syndrome, with emphasis on evidence maturity and clinical translation.<h4>Methods</h4>We conducted a structured narrative review of preclinical, translational, and clinical literature published primarily from 2015 through 2025. The search intentionally included established glucose-lowering therapies and selected mitochondria-directed agents and was not intended to be exhaustive. Because this was not a systematic review, no PRISMA flow diagram, formal risk-of-bias assessment, or standardized evidence grading was performed.<h4>Results</h4>Mitochondrial abnormalities in T2D include impaired oxidative phosphorylation, excessive reactive oxygen species, altered fission-fusion and mitophagy, disrupted calcium handling, metabolic inflexibility, and β-cell bioenergetic failure. The evidence supports a bidirectional model in which inherited susceptibility, aging, nutrient overload, visceral adiposity, lipotoxicity, and inflammation can impair mitochondria, while mitochondrial stress further amplifies insulin resistance and organ dysfunction. Candidate biomarkers and imaging methods remain predominantly research tools because specificity, assay standardization, validated thresholds, and prospective clinical utility are limited. Exercise, weight reduction, GLP-1 receptor agonists, and SGLT2 inhibitors have established clinical benefits and may improve mitochondrial biology indirectly or directly; in contrast, NAD⁺ precursors, targeted antioxidants, mitophagy enhancers, and other dedicated mitochondrial modulators remain investigational, with target engagement generally exceeding demonstrated glycemic benefit.<h4>Conclusion</h4>Mitochondrial dysfunction is best understood as a context-dependent driver, consequence, and amplifier of metabolic disease rather than a universal single cause. Translation will require standardized biomarker panels, noninvasive phenotyping, adequately powered randomized trials with longer follow-up, and prospective identification of patients whose mitochondrial phenotype is likely to be treatment-responsive.